Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.040
-0.030-1.45%
Volume:2.02M
Turnover:4.13M
Market Cap:2.65B
PE:-31.88
High:2.090
Open:2.070
Low:2.020
Close:2.070
52wk High:3.310
52wk Low:1.880
Shares:1.30B
Float Shares:786.49M
Volume Ratio:1.06
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.064
EPS(LYR):-0.064
ROE:-9.86%
ROA:-4.11%
PB:3.23
PE(LYR):-31.88

Loading ...

Mesoblast - Requests Modular Review of Bla for Rexlemestrocel-l in End-stage Heart Failure with Lvad

THOMSON REUTERS
·
Jul 01

Mesoblast - Rexlemestrocel-l Receives Orphan Drug and Rmat Designations

THOMSON REUTERS
·
Jul 01

Founder Led Stocks With Long Term Skin In The Game

Simply Wall St.
·
Jul 01

3 Founder Led Australian Stocks With Insider Skin In The Game

Simply Wall St.
·
Jun 29

Founder Led Stocks Why Investors Are Looking At Flight Centre And 2 More

Simply Wall St.
·
Jun 28

3 Promising ASX Penny Stocks With Over A$60M Market Cap

Simply Wall St.
·
Jun 26

Mesoblast Draws $50 Million From Facility Provided by Shareholder

MT Newswires Live
·
Jun 25

Press Release: Mesoblast Draws US$50 Million from Five-year Non-dilutive Facility

Dow Jones
·
Jun 25

Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?

Simply Wall St.
·
Jun 21

Mesoblast Says JPMorgan Ceases to be Substantial Holder

MT Newswires Live
·
Jun 12

Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX

Simply Wall St.
·
Jun 12

Mesoblast Ltd-ASX CEO Connect Presentation

THOMSON REUTERS
·
Jun 02

ASX Growth Companies With High Insider Ownership

Simply Wall St.
·
Jun 01

ASX Penny Stocks With Market Caps Under A$3B To Consider

Simply Wall St.
·
May 28

Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L

Simply Wall St.
·
May 07

Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?

Simply Wall St.
·
May 02

Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million

Reuters
·
Apr 30

Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

THOMSON REUTERS
·
Apr 30

Stock Track | Mesoblast Plummets 5.41% Intraday Following Quarterly Ryoncil Revenue Report

Stock Track
·
Apr 30

Mesoblast Ltd - Reports Qtrly Ryoncil Net Revenues of $30.3 Mln

THOMSON REUTERS
·
Apr 30